MedClone Inc. said it has entered into an exclusive worldwide licensing agreement withthe University of California that gives the Los Angeles-based biopharmaceutical companycommercial rights to certain monoclonal antibodies.

The antibodies, developed by Dr. Richard Weisbart, chief of rheumatology at the UCLASan Fernando Valley Program, may be useful in the treatment of certain human autoimmunediseases, including rheumatoid arthritis and lupus nephritis, the company said.

MedClone plans to file in the second half of the year to begin trials of its firstproduct, MAb 3E10, a vaccine-therapy for lupus nephritis, a kidney disorder.